Active Biotech AB (DE:BTPC)
FRANKFURT:BTPC
BTPC Stock Chart & Stats
€0.01
<€0.01(14.29%)
At close: 4:00 PM EST
€0.01
<€0.01(14.29%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.02
Previous CloseN/A
Volume20.00K
Average Volume (3M)7.13K
Market Cap
€15.27M
Enterprise Value€15.58M
Total Cash (Recent Filing)€65.10M
Total Debt (Recent Filing)€260.00K
Price to Earnings (P/E)―
Beta-6.65
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,636,067,100
10 Day Avg. Volume2,383
30 Day Avg. Volume7,129
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageZero reported debt in 2025 materially reduces financial distress risk and interest obligations, giving the company structural flexibility. With no bank leverage, management can prioritize R&D spending and partnership deals without fixed debt service, lengthening runway during development cycles.
Narrowing Operating LossesA multi-year trend of smaller operating losses signals improved cost discipline or program prioritization. Sustained narrowing improves the company's ability to extend cash runway, reduces required future financing, and increases the odds management can reach clinical milestones before large new capital raises.
Larger Asset Base In 2025A sizable increase in total assets provides a durable buffer to support ongoing R&D and operational needs. A stronger asset base can reflect successful financing or capitalized investments, improving near-term capacity to fund trials, partnerships, or licensing efforts without immediate dilutive events.
Bears Say
No RevenueThe company generated no product or recurring revenue across 2021–2025, creating a structural dependence on external financing and partnerships. Without a revenue base, sustaining R&D and scaling toward commercialization requires continued funding or successful licensing, raising long-term execution risk.
Persistent Cash BurnMaterial negative operating cash flows over multiple years deplete liquidity and force reliance on capital markets or deals. Even with some improvement, sustained burn rates increase the probability of dilutive financings, limit strategic optionality, and compress time available to achieve value-creating clinical or partnering milestones.
Very Small HeadcountA tiny employee base limits in-house R&D, regulatory, and commercialization capacity, increasing dependence on external contractors and partners. This structural constraint can slow program timelines, raise outsourcing costs, and amplify execution risk when advancing multiple development projects simultaneously.
Active Biotech AB News
BTPC FAQ
What was Active Biotech AB’s price range in the past 12 months?
Active Biotech AB lowest stock price was <€0.01 and its highest was €0.02 in the past 12 months.
What is Active Biotech AB’s market cap?
Active Biotech AB’s market cap is €15.27M.
When is Active Biotech AB’s upcoming earnings report date?
Active Biotech AB’s upcoming earnings report date is May 07, 2026 which is in 28 days.
How were Active Biotech AB’s earnings last quarter?
Active Biotech AB released its earnings results on Feb 12, 2026. The company reported >-€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by >-€0.001.
Is Active Biotech AB overvalued?
According to Wall Street analysts Active Biotech AB’s price is currently Overvalued.
Does Active Biotech AB pay dividends?
Active Biotech AB does not currently pay dividends.
What is Active Biotech AB’s EPS estimate?
Active Biotech AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Active Biotech AB have?
Active Biotech AB has 2,636,067,100 shares outstanding.
What happened to Active Biotech AB’s price movement after its last earnings report?
Active Biotech AB reported an EPS of >-€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Active Biotech AB?
Currently, no hedge funds are holding shares in DE:BTPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Active Biotech AB
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Technical Analysis
Medivir AB
―
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―